Niranjan Kanesa-Thasan - 13 Feb 2023 Form 4 Insider Report for Icosavax, Inc.

Role: Chief Medical Officer
Signature: /s/ Elizabeth Bekiroglu, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 13 Feb 2023
Net transactions value: -$19,183
Form type: 4
Filing time: 15 Feb 2023, 18:58:37 UTC
Previous filing: 05 Jan 2024
Next filing: 17 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ICVX	Common Stock	Sale	$19,183	-1,794	-0.74%	$10.69	239,187	13 Feb 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares withheld by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover the applicable withholding taxes upon settlement of restricted stock units issued to the Reporting Person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.41 to $11.02. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

Represents shares withheld by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover the applicable withholding taxes upon settlement of restricted stock units issued to the Reporting Person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.41 to $11.02. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.